4D Molecular Therapeutics FDMT Derivative Liabilities (Non-Current)
Derivative Liabilities (Non-Current) at other companies
Other financials
Where this comes from
Reported directly by 4D Molecular Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:DerivativeLiabilitiesNoncurrent.
The official record: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about 4D Molecular Therapeutics's derivative liabilities (non-current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is 4D Molecular Therapeutics's derivative liabilities (non-current)?
- 4D Molecular Therapeutics (FDMT) reported derivative liabilities (non-current) of $370K in Q1 2026.
- How has 4D Molecular Therapeutics's derivative liabilities (non-current) changed year-over-year?
- 4D Molecular Therapeutics's derivative liabilities (non-current) increased by 14.9% year-over-year, from $322K to $370K.
- What is the long-term trend for 4D Molecular Therapeutics's derivative liabilities (non-current)?
- Over 5 years (2020 to 2025), 4D Molecular Therapeutics's derivative liabilities (non-current) has grown at a 24.0% compound annual growth rate (CAGR), from $122K to $358K.
- What does derivative liabilities (non-current) mean?
- This metric represents the fair value of financial instruments classified as liabilities that are expected to be settled beyond a twelve-month horizon. These instruments often arise from complex financing arrangements, such as warrants or embedded conversion features, which require periodic revaluation based on market conditions. Monitoring this balance is essential for assessing long-term financial obligations and potential equity dilution risks associated with non-standard debt or equity-linked contracts.